MaxCyte, Inc. MaxCyte Advances Phase I Clinical Trial (9395Q)
24 10월 2019 - 3:00PM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 9395Q
MaxCyte, Inc.
24 October 2019
MaxCyte, Inc.
("MaxCyte" or the "Company")
MaxCyte Advances Phase I Clinical Trial of Lead CARMA(TM)
mRNA-based
Cell Therapy to Third Cohort of Patients
MCY-M11 is being evaluated in relapsed/refractory ovarian cancer
and peritoneal mesothelioma
CARMA platform offers faster manufacturing speeds, broader
therapeutic applications, combination opportunities and repeat
dosing potential
Gaithersburg, MD - 24 October 2019: MaxCyte (LSE: MXCT, MXCR),
the global cell-based therapies and life sciences company,
announces today that, having completed dosing of the second cohort
of patients, clinical investigators have initiated dosing in the
third cohort of patients of MaxCyte's Phase I clinical trial with
the next higher cell dose of MCY-M11. This lead, wholly-owned,
non-viral mRNA-based cell therapy candidate from MaxCyte's CARMA
platform is a mesothelin-targeting chimeric antigen receptor (CAR)
therapy being tested in individuals with relapsed/refractory
ovarian cancer and peritoneal mesothelioma.
The dose escalation trial is evaluating the safety and
tolerability, as well as preliminary efficacy, of MCY-M11
administered intraperitoneally across a series of ascending
dose-level cohorts. In the first two cohorts, the infusion of
MCY-M11 has been well tolerated in all patients treated. No
dose-limiting toxicities, infusion-related adverse events,
on-target or off-target toxicities, or other unwanted events were
observed.
"We are making significant progress with our lead CAR
therapeutic and our proprietary CARMA autologous cell therapy
platform. Furthermore, the on-going trial continues to demonstrate
the feasibility of our one-day cell therapy manufacturing process,"
said Claudio Dansky Ullmann, MD, Chief Medical Officer. "We are
very excited about the potential of MCY-M11 as a new, effective
therapeutic in solid tumors where the majority of patients still
have very limited treatment options."
About the Phase I Clinical Trial
The multi-center, non-randomized, open label, dose-escalation
Phase I clinical trial is evaluating the safety and preliminary
efficacy of intraperitoneal infusions of MCY-M11 in individuals
with platinum-resistant, high-grade, serous adenocarcinoma of the
ovary, primary peritoneum or fallopian tube, or individuals with
advanced peritoneal mesothelioma with recurrence after prior
chemotherapy. MaxCyte anticipates approximately 15 study
participants will be enrolled across the two clinical sites
participating in the study (the National Cancer Institute (NCI) at
the National Institutes of Health (NIH) and Washington University
at St. Louis (WUSTL)). More information about the study can be
found at ClinicalTrials.gov.
About the CARMA Platform
CARMA is MaxCyte's clinical-stage, non-viral, mRNA-based cell
therapy platform that allows for the transfection of mRNA into
cells and provides a simple, rapid-to-manufacture,
dose-controllable product. CARMA requires less than one day for
manufacture therapies for patients, where existing CAR-T therapies
require one to two weeks or more to manufacture. MaxCyte's
wholly-owned lead CARMA candidate, MCY-M11, is currently being
evaluated in a Phase I clinical trial in patients with advanced
ovarian cancer and peritoneal mesothelioma. MaxCyte management is
evaluating independent sources of financing for CARMA. More
information on the CARMA platform and pipeline is available at
www.maxcyte.com/car/.
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. MaxCyte is developing novel CARMA
therapies for its own pipeline, with its first drug candidate in a
Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary
therapeutic platform for autologous cell therapy for the treatment
of solid cancers. In addition, through its life sciences business,
MaxCyte leverages its Flow Electroporation Technology to enable its
biopharmaceutical partners to advance the development of innovative
medicines, particularly in cell therapy. MaxCyte has placed its
flow electroporation instruments worldwide, including with all of
the top ten global biopharmaceutical companies. The Company now has
more than 80 partnered programme licenses in cell therapy with more
than 45 licensed for clinical use, including six commercial
licenses. Aggregate potential pre-commercial milestones from all
license deals total more than $450m. With its robust delivery
technology platform, MaxCyte helps its partners to unlock the full
potential of their products. For more information, visit
www.maxcyte.com.
###
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 (MAR).
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.
Chris Welsh com
Sukaina Virji
--------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESLFFSIIFLVFIA
(END) Dow Jones Newswires
October 24, 2019 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Maxcyte (LSE:MXCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024